Anzeige
Mehr »
Login
Donnerstag, 28.03.2024 Börsentäglich über 12.000 News von 687 internationalen Medien
Spezial am Donnerstag: Rallye II. - Neuer Anstoß, News und was die Börsencommunity jetzt nicht verpassen will…
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
Dow Jones News
1.106 Leser
Artikel bewerten:
(2)

MagForce AG: 'NanoTherm School' successfully enters its second round with Module B

DGAP-Media / 2019-12-11 / 09:30 
 
MagForce AG: _'NanoTherm School'_ successfully enters its second round with 
*Module B* 
 
· _MagForce successfully hosted the second session of its 
practice-oriented, unique, multifaceted application training for the use 
of the NanoTherm therapy system in treating brain tumors_ 
 
· _The NanoTherm School is part of MagForce's commitment to further 
optimize the therapy system and educate medical professionals in its use 
to provide brain tumor patients with the best care possible in addition to 
a broad geographical coverage to provide greater accessibility_ 
 
· _Participants included the team of Prof. Dr. med. habil. Jan-Peter 
Warnke, Senior Consultant in the Neurosurgical Clinic at the Paracelsus 
Clinic in Zwickau, where now MagForce's NanoTherm therapy system is 
available_ 
 
*Berlin, Germany and Nevada, USA, December 11, 2019* - With "Module B - 
Advanced Course 1: - stereotactic Instillation" MagForce AG (Frankfurt, 
Scale, Xetra: MF6, ISIN: DE000A0HGQF5), a leading medical device company in 
the field of nanomedicine focused on oncology, conducted the second round of 
its 'NanoTherm School' in November. The application training series was 
launched in January 2019 to provide the highest quality of treatment through 
ongoing support for physicians and certify surgeons in the use of the 
innovative NanoTherm technology. Same as the first session, "Module A - The 
Basics", which took place at the end of January 2019, Module B, focusing on 
advanced techniques, was met with great excitement from participants. 
 
The _NanoTherm School_ is part of MagForce's roll-out strategy focusing on a 
broad geographic coverage to provide greater availability while also 
constantly working on further optimizing its therapy system and educating 
medical professionals in its use to provide brain tumor patients with the 
best care possible. The training concept of _NanoTherm School_ was developed 
in close collaboration with Prof. Dr. Walter Stummer, PD Dr. Dr. Oliver 
Grauer, and Dr. Michael Schwake, University Hospital Münster, and PD Dr. 
Johannes Wölfer, Hufeland Klinikum GmbH Mühlhausen, drawing on their 
long-standing experience in the treatment of brain tumor patients with the 
NanoTherm therapy system. 
 
Participants again included the team of Prof. Dr. med. habil. Jan-Peter 
Warnke, Senior Consultant in the Neurosurgical Clinic at the Paracelsus 
Clinic in Zwickau, with whom MagForce entered into a cooperation agreement 
in June 2019. Installation of the mobile treatment center was completed in 
summer. The NanoActivator is now ready for use at the clinic after receipt 
of final approval and and is now available for the treatment of patients 
with brain tumors. 
 
*Prof. Dr. med. habil. Jan-Peter Warnke*, Senior Consultant in the 
Neurosurgical Clinic at the Paracelsus Clinic in Zwickau*, 
*added_"Innovation is extremely important in medicine and has served our 
patients well. Obtaining the appropriate training in new technologies and 
techniques is a vital part of adopting these advances into our standard 
treatment regimens. Practical trainings such as MagForce's NanoTherm School 
are therefore very welcomed as they allow neurosurgeons to ease into the 
method while developing the necessary skills.__Thanks to the excellent 
preparation and support of the MagForce team, as well as the opportunity to 
practice NanoTherm therapy in the most practical and extremely 
well-structured way, we are well prepared for the use of the therapy system 
at our clinic starting immediately. The use of new teaching methods for 
advanced technologies helps us to bring outstanding inventions to 
patients."_ 
 
About _NanoTherm School_ 
Targeted towards medical professionals working in the fields of 
neuro-surgery and neuro-oncology, the _NanoTherm Therapy School_ series aims 
at introducing participants to the theoretical knowledge and practical 
techniques required to successfully apply MagForce's NanoTherm technology 
for the treatment of brain tumors. In practicing their skills with human 
specimens, participants are able to familiarize themselves with the 
procedures and device usages in a stress-free environment under largely real 
operating conditions. 
 
The _NanoTherm School_ is designed in three consecutive modules allowing 
participants to gain knowledge and understanding of MagForce's NanoTherm 
technology starting from basic application techniques (nanopasting) and 
building to advanced techniques and new surgical application forms in the 
final module (Module C). The practical section of the course is complemented 
by lectures on directly relevant aspects of NanoTherm therapy, as well as 
sample preparation and surgical videos. The equipment and facilities used 
during the course meet the requirements of today's state-of-the-art surgical 
equipment. 
 
*For more information about NanoTherm School, please contact:* 
Dipl.-Ing. Tobias Hanitsch (thanitsch@magforce.com) 
Marcel Pilz (mpilz@magforce.com) 
 
*About MagForce AG and MagForce USA, Inc.* 
MagForce AG, listed in the Scale segment of the Frankfurt Stock Exchange 
(MF6, ISIN: DE000A0HGQF5), together with its subsidiary MagForce USA, Inc. 
is a leading medical device company in the field of nanomedicine focused on 
oncology. The Group's proprietary NanoTherm therapy system enables the 
targeted treatment of solid tumors through the intratumoral generation of 
heat via activation of superparamagnetic nanoparticles. 
 
NanoTherm(R), NanoPlan(R), and NanoActivator(R) are components of the 
therapy and have received EU-wide regulatory approval as medical devices for 
the treatment of brain tumors. MagForce, NanoTherm, NanoPlan, and 
NanoActivator are trademarks of MagForce AG in selected countries. 
 
*For more information, please visit: www.magforce.com [1]. 
Get to know our Technology: video (You Tube) [2] 
Stay informed and subscribe to our mailing list [3]* 
 
*Disclaimer * 
This release may contain forward-looking statements and information which 
may be identified by formulations using terms such as "expects", "aims", 
"anticipates", "intends", "plans", "believes", "seeks", "estimates" or 
"will". Such forward-looking statements are based on our current 
expectations and certain assumptions, which may be subject to a variety of 
risks and uncertainties. The results actually achieved by MagForce AG may 
substantially differ from these forward-looking statements. MagForce AG 
assumes no obligation to update these forward-looking statements or to 
correct them in case of developments, which differ from those, anticipated. 
 
*Contact:* 
Barbara von Frankenberg 
Vice President 
Communications & Investor Relations 
T +49-30-308380-77 
E-Mail: bfrankenberg@magforce.com 
 
End of Media Release 
 
Issuer: MagForce AG 
Key word(s): Health 
 
2019-12-11 Dissemination of a Press Release, transmitted by DGAP - a service 
of EQS Group AG. 
The issuer is solely responsible for the content of this announcement. 
 
The DGAP Distribution Services include Regulatory Announcements, 
Financial/Corporate News and Press Releases. 
Archive at www.dgap.de 
Language:    English 
Company:     MagForce AG 
             Max-Planck-Straße 3 
             12489 Berlin 
             Germany 
Phone:       +49 (0)30 308 380 0 
Fax:         +49 (0)30 308 380 99 
E-mail:      info@magforce.com 
Internet:    www.magforce.com 
ISIN:        DE000A0HGQF5 
WKN:         A0HGQF 
Indices:     Scale 30 
Listed:      Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt 
             (Scale), Stuttgart, Tradegate Exchange 
EQS News ID: 932409 
 
End of News DGAP Media 
 
932409 2019-12-11 
 
 
1: https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=8c9fb96f72ca3bbe10dd7f041cbe6fa6&application_id=932409&site_id=vwd&application_name=news 
2: https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=fee20ce56f7c48d1562a60533ead43c9&application_id=932409&site_id=vwd&application_name=news 
3: https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=f35fad65a8bc4664a072c1fef1651402&application_id=932409&site_id=vwd&application_name=news 
 

(END) Dow Jones Newswires

December 11, 2019 03:30 ET (08:30 GMT)

Großer Dividenden-Report 2024 von Dr. Dennis Riedl
Der kostenlose Dividenden-Report zeigt ganz genau, wo Sie in diesem Jahr zuschlagen können. Das sind die Favoriten von Börsenprofi Dr. Dennis Riedl
Jetzt hier klicken
© 2019 Dow Jones News
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.